Collplant biotechnologies provides business updates and third quarter 2021 financial results

Rehovot, israel, nov. 18, 2021 /prnewswire/ -- collplant biotechnologies (nasdaq: clgn), a regenerative and aesthetic medicine company developing innovative technologies and products for tissue regeneration and organ manufacturing, today announced business updates and financial results for the third quarter ended september 30, 2021. "the recent commercial launch of collink.3d represents an important inflection point for collplant in its efforts to become a market leader in the field of regenerative medicine.
CLGN Ratings Summary
CLGN Quant Ranking